Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cixutumumab - Eli Lilly and Company

Drug Profile

Cixutumumab - Eli Lilly and Company

Alternative Names: A12; IMC-A12; LY3012217; NSC 742460

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly and Company; ImClone Systems; M. D. Anderson Cancer Center; National Cancer Institute (USA)
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Thymoma

Most Recent Events

  • 06 Sep 2018 Discontinued - Phase-II for Head and neck cancer (Combination therapy, Neoadjuvant therapy) in USA (IV) (Eli Lilly pipeline, September 2018)
  • 06 Sep 2018 Discontinued - Phase-II for Head and neck cancer (Neoadjuvant therapy, Monotherapy) in USA (IV) (Eli Lilly pipeline, September 2018)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top